Drugs in Dev. Neurology
Phase IV
Switzerland 
Lead Product(s) : Ofatumumab,13-Valent Pneumococcal Conjugate Vaccine,Tetanus Toxoid Vaccine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in multiple sclerosis (MS).
Product Name : Kesimpta
Product Type : Antibody
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Ofatumumab,13-Valent Pneumococcal Conjugate Vaccine,Tetanus Toxoid Vaccine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ofatumumab
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Genmab
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ofatumumab is an anti-CD20 IgG1κ human monoclonal antibody used for treatment for chronic lymphocytic leukemia and relapsing forms of multiple sclerosis (MS).
Product Name : Kesimpta
Product Type : Antibody
Upfront Cash : Inapplicable
July 10, 2021
Lead Product(s) : Ofatumumab
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Genmab
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first randomized, double blind, head-to-head study of Aimovig® (erenumab) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints.
Product Name : Aimovig
Product Type : Antibody
Upfront Cash : Inapplicable
February 11, 2020
Reset All
